These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 1465872

  • 1. One-year randomized controlled trial with omega-3 fatty acid-fish oil in clinical renal transplantation.
    Berthoux FC, Guerin C, Burgard G, Berthoux P, Alamartine E.
    Transplant Proc; 1992 Dec; 24(6):2578-82. PubMed ID: 1465872
    [No Abstract] [Full Text] [Related]

  • 2. Azathioprine can be safely stopped in triple drug induction protocols including cyclosporine and steroids in renal transplantation.
    Pallardó LM, Sánchez J, Sánchez P, García J, Orero E, Beneyto I, Ros F.
    Transplant Proc; 1992 Dec; 24(6):2604-5. PubMed ID: 1465880
    [No Abstract] [Full Text] [Related]

  • 3. Results of a 1-year randomized controlled trial with omega-3 fatty acid fish oil in renal transplantation under triple immunosuppressive therapy.
    Maachi K, Berthoux P, Burgard G, Alamartine E, Berthoux F.
    Transplant Proc; 1995 Feb; 27(1):846-9. PubMed ID: 7879202
    [No Abstract] [Full Text] [Related]

  • 4. Enhanced renal graft survival in HLA-A mismatched transplants.
    Bućin D, Ekberg H, Lindholm A, Persson H, Tufvesson G, Albrechtsen D.
    Transplant Proc; 1992 Dec; 24(6):2473-4. PubMed ID: 1465837
    [No Abstract] [Full Text] [Related]

  • 5. Elective cyclosporine withdrawal in renal transplant recipients maintained on triple therapy.
    Keitel E, Bittar AE, Losekann A, Deboni L, Ceretta F, Goldani JC, Garcia VD.
    Transplant Proc; 1992 Dec; 24(6):2606-8. PubMed ID: 1465881
    [No Abstract] [Full Text] [Related]

  • 6. Low-dose triple immunosuppression for HLA identical sibling kidney transplants.
    Schweizer RT, Roper L, Hull D, Bartus SA.
    Transplant Proc; 1992 Dec; 24(6):2609. PubMed ID: 1465882
    [No Abstract] [Full Text] [Related]

  • 7. Analysis of risk factors affecting the outcome of primary living donor renal transplantation in Korea.
    Park K, Kim YS, Kim SI.
    Transplant Proc; 1992 Dec; 24(6):2426-7. PubMed ID: 1465816
    [No Abstract] [Full Text] [Related]

  • 8. Six-year experience with a triple drug protocol in renal transplantation: analysis of risk factors.
    Pallardó LM, Sánchez P, Sánchez J, García J, Orero E, Beneyto I, Cruz JM.
    Transplant Proc; 1992 Dec; 24(6):2714-5. PubMed ID: 1465911
    [No Abstract] [Full Text] [Related]

  • 9. Repeated HLA mismatch in multiple kidney transplantation: preliminary results of 146 retransplantations in the cyclosporine era.
    Gnant MF, Sautner T, Rosenmayr A, Muehlbacher F.
    Transplant Proc; 1992 Dec; 24(6):2466-8. PubMed ID: 1465833
    [No Abstract] [Full Text] [Related]

  • 10. Low-dose OKT3 for cadaveric renal transplantation.
    Schweizer RT, Roper L, Hull D, Bartus SA.
    Transplant Proc; 1992 Dec; 24(6):2592-3. PubMed ID: 1465875
    [No Abstract] [Full Text] [Related]

  • 11. DR6 compatibility and kidney graft survival.
    Correia AM, de Costa AG, Reis P, Rego F, Sampaio MJ, Caetano JM, Pena JR.
    Transplant Proc; 1992 Dec; 24(6):2472. PubMed ID: 1465836
    [No Abstract] [Full Text] [Related]

  • 12. Living-unrelated renal transplantation.
    Simforoosh N, Bassiri A, Amiransari B, Gol S.
    Transplant Proc; 1992 Dec; 24(6):2421-2. PubMed ID: 1465814
    [No Abstract] [Full Text] [Related]

  • 13. Cyclosporine-related hypercoagulability: fact or fiction?
    Edwards CM, Morgan JD, Donnelly PK.
    Transplant Proc; 1992 Dec; 24(6):2616-7. PubMed ID: 1465885
    [No Abstract] [Full Text] [Related]

  • 14. Area under the curve of cyclosporine pharmacokinetics: comparison of the characteristics of the pure drug and metabolites.
    Foradori AC, Martínez L, Vacarezza A, Elberg A, Mella G, Loveluck A, Pinto C.
    Transplant Proc; 1992 Dec; 24(6):2614-5. PubMed ID: 1465884
    [No Abstract] [Full Text] [Related]

  • 15. Delayed omega-3 fatty acid supplements in renal transplantation. A double-blind, placebo-controlled study.
    Bennett WM, Carpenter CB, Shapiro ME, Strom TB, Hefty D, Tillman M, Abrams J, Ryan D, Kelley VR.
    Transplantation; 1995 Feb 15; 59(3):352-6. PubMed ID: 7871564
    [Abstract] [Full Text] [Related]

  • 16. Chronic rejection of renal allografts with four immunosuppressive regimens.
    Isoniemi H, Ahonen J, Krogerus L, Eklund B, Höckerstedt K, Salmela K, Häyry P.
    Transplant Proc; 1992 Dec 15; 24(6):2716-7. PubMed ID: 1465912
    [No Abstract] [Full Text] [Related]

  • 17. Comparison between donor-specific transfusions with conventional immunosuppression and triple therapy including cyclosporine in living related donor kidney transplantation.
    Arbelaez M, Mejia G, Henao JE, Garcia A, Arango JL, Velasquez A, Restrepo J, Garcia LF.
    Transplant Proc; 1992 Dec 15; 24(6):3096-7. PubMed ID: 1466072
    [No Abstract] [Full Text] [Related]

  • 18. Influence of recipient's HLA type on the outcome of renal transplantation.
    Forsberg B, Ekberg H, Johnson U.
    Transplant Proc; 1992 Dec 15; 24(6):2463-5. PubMed ID: 1465832
    [No Abstract] [Full Text] [Related]

  • 19. The effects of dietary supplementation with fish oil on renal function and the course of early postoperative rejection episodes in cyclosporine-treated renal transplant recipients.
    Homan van der Heide JJ, Bilo HJ, Donker AJ, Wilmink JM, Sluiter WJ, Tegzess AM.
    Transplantation; 1992 Aug 15; 54(2):257-63. PubMed ID: 1496538
    [Abstract] [Full Text] [Related]

  • 20. Role of maintenance immunosuppression and methylprednisolone in OKT3-induced cytokine release.
    Peces R, Urra JM, Gorostidi M, López-Larrea C.
    Transplant Proc; 1992 Dec 15; 24(6):2596-9. PubMed ID: 1465877
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.